Can You Hack Your Cycle?

Try harmonizing your hormones by 'cycle syncing' your nutrition

Sep 18, 2024

5 min

Lindsey Davis, M.D., MPH

You’ve probably heard of – or experienced for yourself – that women crave chocolate due to PMS (premenstrual syndrome) before or even during their cycle. Some attribute this craving to a loss of riboflavin during this time.


But it could also be a response to the body’s increase in hormones that contribute to cravings for sweets and fats, and chocolate has both! Ignoring those cravings isn’t going to work. However, there are ways to satisfy your body’s needs without breaking the calorie bank, overindulging in food or reaching for unhealthy options.


The cycle


There are essentially two phases in the menstrual cycle — follicular and luteal — which are triggered by hormonal changes. “Cycle syncing” is the process of altering diet and activity according to a woman’s naturally occurring menstrual phases each month.


When you consider nutrition “cycle syncing,” which is tailoring your nutrition with your menstrual cycle throughout the month, it’s helpful to break it into four separate components:


  1. Menstruation (beginning of menstruation).
  2. Follicular.
  3. Ovulation (1st day of luteal).
  4. Luteal.


What does this mean? It means this complex cycle is controlled by female hormones that cause regular bleeding (periods). Estrogen is one of the major players that helps regulate a woman’s menstrual cycle and is produced mainly by the ovaries, the same two small glands that store hundreds of thousands of tiny eggs for release over a woman’s lifetime.



Eating for PMS in cycle stages


Phase 1: Menstruation – “Aunt Flo” comes to visit (3-7 days)

During the menstrual period, the most work happens during the first three days. This is when a woman’s flow arrives and pain onsets in the pelvis, legs, back and other areas. This is also when the most blood is lost. The cramps a woman feels serve a purpose. They are a symptom of the uterus contracting, helping to shed the endometrium (the lining of the uterus), which you may know as Aunt Flo coming to visit, also known as menstrual bleeding.


Focusing on good sources of nutrition with magnesium in them may help reduce the severity of symptoms for better sleep, headaches, muscle soreness in the uterus and cramping, swelling and bloating and mood changes.


Healthy fats can be useful during this phase since levels of estrogen and progesterone are typically low. We need healthy fats to help generate any kind of hormones. Look for good sources of healthy fats in seafood rich in omega-3 fatty acids, avocados, olive oil, sardines in oil, nuts and seeds, fiber, apples, berries, ground flax seed and oatmeal.


Phase 2: Follicular – release the kraken! (7-10 days)

Let’s face it, during the second stage of a woman’s cycle, your body is about to drop the mic! Well, not the mic per se, but your body is preparing to release an egg. That’s a lot of work. During this phase, hormones are released to signal the production of follicles on the surface of an ovary. A handful will enlarge, but only the largest and strongest follicle will ultimately release an egg during ovulation. This plays the biggest role in the length of your cycle.


At the very same time, the endometrium starts to thicken in case you’re getting ready to have a baby. The last five days of this phase, plus the ovulation day (the day the egg drops), are your fertile window (baby-making time!). This is when you are most likely to become pregnant if you have sexual intercourse without using birth control.


Focus on complex carbohydrates during this phase. Complex carbohydrates keep the insulin-glucagon ratio even and can help manage depression, fatigue and insomnia.


Pro Tip: Between cycling, zinc can be helpful for ovulation and potentially help to support the egg quality. For women who are looking to conceive, they may want to consider using more zinc in their diet or with a supplement leading up to the follicular phase. Talk with your health care provider to see if this is a helpful option for you.


Phase 3: Ovulation phase – there can be only one! (2-4 days)

The three to five days leading up to ovulation and the day of ovulation itself are the most fertile. Ovulation begins on the day the egg is released from the egg follicle on the ovary. Remember when you were little and found a dandelion seedling in the grass? You grabbed it and blew on the seedlings to release them into the wind. This is similar except it’s just one egg being released.


Protein is your friend during this phase. Protein will help keep your blood sugars steady, keep you feeling full and prevent cravings.


Phase 4: Luteal (premenstrual) phase – winter is coming! (10-14 days)

The luteal phase starts on the day the egg drops, also known as ovulation day. This happens anytime from day 7 to day 22 of a normal menstrual cycle. After the teen years and before perimenopause (the time before menopause), the luteal phase is very predictable. It normally lasts 13 to 15 days from ovulation until menstrual bleeding starts a new cycle. These two weeks are also known as the premenstrual period.


It’s very common to have symptoms during all or part of the luteal phase. You may feel irritable and cranky, gain water weight and feel bloated. A day or more before your period, you may start to have pain (cramps) in your belly, back or legs. It’s normal to have less energy at this time. Don’t panic, and don’t get down on yourself for needing to rest or nap. You may also have headaches, diarrhea or constipation, nausea or dizziness.


When premenstrual symptoms make your daily life difficult, you are said to have premenstrual syndrome (PMS). Good dietary sources during the luteal phase should include calcium. Calcium can help reduce the severity of PMS symptoms, including bloating, depression, pain, mood swings and food cravings.


Pro tip: It may be difficult to get all the calcium necessary to help with general PMS symptoms. While we recommend getting as much calcium as possible in your diet, check with your health care provider for guidance on nutrition and supplementation. According to the American College of Obstetricians and Gynecologists, 1,200 milligrams of magnesium is usually recommended to help reduce the physical and mood symptoms of PMS. Everyone metabolizes food and supplementation differently. Results will vary.


The role of iron

Consider increasing iron and iron sources, especially during the luteal phase leading up to the menstruation phase. The leading cause of iron deficiency and anemia is a woman’s cycle. The more that women boost their iron stores before their menstruation cycle, the better. Look to increase iron consumption through animal sources, legumes or fortified cereals. Some women might need supplementation or other medical interventions. Sometimes, other conditions cause heavy menstrual cycles or reasons for medical intervention.


Follow up with your health care provider


Women may have menstrual-related conditions needing treatment beyond lifestyle changes alone. Seek care for:

  • Irregular periods (not due to medication or breastfeeding).
  • Heavy menstrual bleeding or severe menstrual pain.
  • Significant depression and/or anxiety around the menstruation cycle.


Menstrual cycles can have many different symptoms and associated medical conditions. Making lifestyle modifications is helpful, but if you’re experiencing severe or concerning symptoms, these should always be discussed with a health care provider.

Connect with:
Lindsey Davis, M.D., MPH

Lindsey Davis, M.D., MPH

OB/GYN

Dr. Lindsey Davis is an ob/gyn at ChristianaCare.

Obstetrics & Gynecology
Powered by

You might also like...

Check out some other posts from ChristianaCare

3 min

New Study Finds Most Patients Can Safely Continue Weight Loss and Diabetes Drugs Before Gynecologic Surgery

Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”

1 min

Two Research Scientists at the Cawley Center for Translational Cancer Research Earn Top Honors at UD Biology Research Day

Two rising cancer researchers from ChristianaCare’s Cawley Center for Translational Cancer Research were recognized for outstanding scientific contributions at the University of Delaware’s Annual Biology Research Day Conference on January 30, 2026. The awards highlight the strength and impact of colorectal cancer research underway at the Cawley Center. Anh Nguyen, a third year Ph.D. student, received the conference’s first place poster award for his project, “FGF19/FGFR4 Axis: A Key Driver in Tumor Growth and Treatment Resistance in Colorectal Cancer.” His research explores a signaling pathway that may lead to new strategies for targeting treatment resistant disease. Molly Lausten, a fifth year Ph.D. student, earned third place for her presentation, “Investigating the role of miR 27a 3p in the WNT signaling pathway and chemoresistance in colorectal cancer stem cells.” Her work examines a key microRNA that may influence resistance to therapy, a major challenge in treating aggressive tumors. “These awards reflect far more than individual excellence,” said Bruce M. Boman, M.D., Ph.D., MSPH, FACP, senior scientist and director of Cancer Genetics at the Cawley Center. “They show the power of rigorous, curiosity driven science to move the field forward. Molly and Anh are tackling some of the hardest questions in colorectal cancer, and their success speaks to the innovative environment we are building at ChristianaCare. I could not be more proud of their achievement and their commitment to improving outcomes for patients.”

3 min

Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients

Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”

View all posts